In this issue:
First patient decision aid for adults with AD
A step towards precision medicine: Assay identifies JAK inhibitor responders
Clinical improvements with therapy mirrored by resolution of bacterial dysbiosis
Urbanisation factors exacerbate AD risk
Maternal Type 1 diabetes linked to risk of childhood AD
Negative medication beliefs are a barrier to topical therapy adherence
Serum TARC is a biomarker of AD severity and prognosis in infants
Better benefit–risk profile with dupilumab vs upadacitinib
German study underscores need for timely escalation to targeted therapies
Meta-analysis suggests upadacitinib is the most potent JAK inhibitor
Please login below to download this issue (PDF)